>

Home

Uddin Lab News

Marcell Paguaga’s paper, “A novel optical imaging probe for targeted visualization of NLRP3 inflammasomes in a mouse model of age-related macular degeneration,” has been accepted for publication in Frontiers in Medicine. Congrats Marcell !! Great job

The Uddin Lab received a Reeves Foundation Grant 2022-2023 ($47,100) for a new OptoDrum automated optokinetic measurement system and Scotopic Experiment system.

The Uddin Lab has received American Diabetes Association Innovative Basic Science Award 2022. Funding starts date Nov 2022 to Nov 2025.

Dr. Uddin has received an International Retinal Research Foundation (IRRF) pilot Grant support for age-related macular degeneration (AMD) research. Starting from Oct 2022 to Sep 2024.

Marcell’s poster “Development of an optical imaging probe for targeted visualization of NLRP3 inflammasome in a mouse model of age-related macular degeneration (AMD)” was selected as Hot-Topic at ARVO 2022! Congrats Marcell!

Dr. Uddin presented a new gene therapy method “Inhibition of HIF-1α mRNA could regulate monocyte functions and could inhibit neovascularization in a mouse model of proliferative retinopathy” at ARVO 2022!

A new patent filed from Uddin Lab: “PROBES AND METHODS FOR TARGETED VISUALIZATION OF NLRP3 INFLAMMASOMES” in 2022.

Patent from Uddin Lab “NANOGOLD-DNA BIOCONJUGATES AND METHODS OF USE THEREOF” entered into the next level, non-provisional utility patent in 2022.

Uddin Lab received Reeves Foundation Grant 2021-2022 ($50,000) for a new OCT2/Laser for Micron-IV optical imaging system.

The BrightFocus grant was approved July 1st 2019 to June 30th 2022 and Reeves Foundation as second term for 2022.

Imam Uddin received a Reeves Foundation Award of $80,000 (Oct 2020-Aug 2021) for Age-related Macular Degeneration (AMD) research.

The Uddin Lab received a BrightFocus Foundation Macular Degeneration Award of $200,000 (July 1, 2019-June 30, 2021 to study a novel nanomedicine, developed in the Uddin Lab, for the treatment of age-related macular degeneration.

Uddin Paper Makes ACS Chemical Biology Cover!

Selective visualization of monocyte-derived macrophages could be a powerful method to predict the onset and progression of ocular-angiogenesis at molecular level. In this report the authors described the synthesis of a new hybrid nanoparticle to visualize HIF-1a mRNA selectively in monocyte-derived macrophages in a mouse model of ocular-angiogenesis (neovascularization).

“Visualizing HIF-1 mRNA in a sub-population of bone marrow derived cells to predict retinal neovascularization” has been selected for ACS Chemical Biology Cover for the issue. See large cover image.

Imaging Hypoxia-induced Retinal Neovascularization

Two pioneering technologies may help predict vision loss from retinopathies. By Imam Uddin & John Penn

New Lab Space

Click here to see our new lab space!

Welcome to the Imam Uddin lab. Our research is focused on the development of molecular imaging technologies including optical imaging, optical coherence tomography (OCT) and nanoscale engineering to identify molecular targets for early disease detection and treatments in ophthalmology, vascular medicine and oncology.

We are currently using optical imaging techniques and nanotechnology-based approaches for diagnosis and drug delivery in preclinical models of diabetic retinopathy (DR), age-related macular degeneration (AMD), retinopathy of prematurity (ROP) and retinal vein occlusion (RVO).

Executive Guest Editor: Experimental Eye Research 

Title of the special issue: Molecular Imaging of the Retina

Submissions to special issue: https://www.sciencedirect.com/special-issue/318962/molecular-imaging-of-the-retina

Cover Art from Uddin Lab:

Microcirculation-2024-Jamal-Cover-Image

BME-3890-04 Special Topic: Nuclear Medicine and Molecular Imaging